Nuclear Factor κB Signaling in Atherogenesis | Arteriosclerosis, Thrombosis, and Vascular Biology
Cancers | Free Full-Text | Targeting NF-κB Signaling for Multiple Myeloma | HTML
Chemical structures of leflunomide and its metabolite A77 1726. | Download Scientific Diagram
The immunomodulatory drug Leflunomide inhibits cell cycle progression of B-CLL cells | Leukemia
Effect of leflunomide (2.5, 5 or10 mg/kg) on hepatic immunostaining for... | Download Scientific Diagram
Transdermal delivery of inflammatory factors regulated drugs for rheumatoid arthritis - Pharma Excipients
New Drugs for Rheumatoid Arthritis | NEJM
HIF1α inhibition facilitates Leflunomide-AHR-CRP signaling to attenuate bone erosion in CRP-aberrant rheumatoid arthritis | Nature Communications
Inhibiting NF-κB activation by small molecules as a therapeutic strategy. - Abstract - Europe PMC
Cancers | Free Full-Text | Targeting NF-κB Signaling for Multiple Myeloma | HTML
NF-κB activation as a pathological mechanism of septic shock and inflammation | American Journal of Physiology-Lung Cellular and Molecular Physiology
The role of Chinese herbal medicine in the management of adverse drug reactions of leflunomide in treating rheumatoid arthritis - ScienceDirect
Individualization of leflunomide dosing in rheumatoid arthritis patients | Personalized Medicine
NF-κB activation as a pathological mechanism of septic shock and inflammation | American Journal of Physiology-Lung Cellular and Molecular Physiology
Individualization of leflunomide dosing in rheumatoid arthritis patients | Personalized Medicine
NF-κB as a potential therapeutic target in osteoarthritis and rheumatoid arthritis - ScienceDirect
HIF1α inhibition facilitates Leflunomide-AHR-CRP signaling to attenuate bone erosion in CRP-aberrant rheumatoid arthritis | Nature Communications
Leflunomide an immunomodulator with antineoplastic and antiviral potentials but drug-induced liver injury: A comprehensive review - ScienceDirect
Effects of Leflunomide on Hyaluronan Synthases (HAS): NF-κB-Independent Suppression of IL-1-Induced HAS1 Transcription by Leflunomide | The Journal of Immunology
Leflunomide–hydroxychloroquine combination therapy in patients with primary Sjögren's syndrome (RepurpSS-I): a placebo-controlled, double-blinded, randomised clinical trial - The Lancet Rheumatology
NF-κB as a potential therapeutic target in osteoarthritis and rheumatoid arthritis - ScienceDirect
Leflunomide | C12H9F3N2O2 - PubChem
Effects of Leflunomide on Hyaluronan Synthases (HAS): NF-κB-Independent Suppression of IL-1-Induced HAS1 Transcription by Leflunomide | The Journal of Immunology
NF-κB signaling in rheumatoid arthritis with focus on fibroblast-like synoviocytes | Autoimmunity Highlights | Full Text
